Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Preladenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8243159 | 0.93 | ADORA2A (0.87) | ADORA2AADORA1 | |
| SCHEMBL21832807 | 0.92 | ADORA2A (0.87) | ADORA2AADORA1 | |
| SCHEMBL12969346 | 0.92 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL8287839 | 0.92 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL21833625 | 0.92 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL30543453 | 0.92 | ADORA2A (0.88) | ADORA2AADORA1 | |
| SCHEMBL30858798 | 0.92 | ADORA2A (0.88) | ADORA2AADORA1 | |
| SCHEMBL8243358 | 0.91 | ADORA2A (0.85) | ADORA2AADORA1 | |
| SCHEMBL21833111 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL14922357 | 0.91 | ADORA2A (0.83) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683923-A1 | HYDROGEN SULFATE COMPLEXES, INCLUDING SALTS, CRYSTALLINE FORMS, AND HYDRATES AND SOLVATES OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2026-01-28 | — | — | EP | claimed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | claimed |
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | claimed |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | claimed |
| CN-119452086-A | GAPMER antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4489759-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | claimed |
| EP-4489760-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | claimed |
| EP-3987030-A2 | PPM1A INHIBITORS AND METHODS OF USING SAME | Quralis Corporation (US) | 2022-04-27 | — | — | EP | claimed |
| US-11298350-B2 | Subcutaneous delivery of polymer conjugates of therapeutics agents | SERINA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| US-11246871-B2 | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias | NORTHWESTERN UNIVERSITY (US) | 2022-02-15 | — | — | US | claimed |
| WO-2022025499-A1 | NOVEL THERAPEUTIC METHOD FOR ENHANCING MITOCHONDRIAL FUNCTION, TREATING MITOCHONDRIAL DISEASES THEREBY, AND COMPOUNDS USED THEREIN | STANDIGM INC. (KR) | 2022-02-03 | — | — | WO | claimed |
| US-20210338672-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | iTeos Belgium SA (BE) | 2021-11-04 | — | — | US | claimed |
| EP-3856181-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | iTeos Belgium SA (BE) | 2021-08-04 | — | — | EP | claimed |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| WO-2020065036-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | ITEOS THERAPEUTICS S.A. (BE) | 2020-04-02 | — | — | WO | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| WO-2012127472-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PRELADENANT AND RELATED COMPOUNDS | MAPI PHARMA LTD. (IL) | 2012-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADORA2A 1752/4885ADORA1 2861/4885 |
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | ADORA2A, P2RX2, ADORA2B | ADORA2A 1/4885ADORA1 12/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | ADORA2A 1313/4885ADORA1 2465/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885 |
| US-11298350-B2 | Subcutaneous delivery of polymer conjugates of therapeutics agents | CD44, CD47, LNPEP | ADORA2A 4537/4885ADORA1 4600/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | ADORA2A 1416/4885ADORA1 2549/4885 |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 5/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADORA2A 1752/4885ADORA1 2861/4885 |
| US-11246871-B2 | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias | ADORA2A, PARK7, ADORA3 | ADORA2A 1/4885ADORA1 6/4885 |
| US-20210338672-A1 | USE OF AN INHIBITOR OF AN ENT FAMILY TRANSPORTER IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST | SLC29A1, SLC29A2, ENTPD5 | ADORA2A 11/4885ADORA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.